BRAF and lung adenocarcinoma: The emergence of mutations in KRAS, TP53, and CDKN2A has been hypothesized as a resistance mechanism to the BRAF inhibitor, dabrafenib in the clinics for BRAF mutated lung adenocarcinoma (60).